270 reports of this reaction
1.9% of all LIDOCAINE HYDROCHLORIDE ANHYDROUS reports
#12 most reported adverse reaction
INFUSION SITE SWELLING is the #12 most commonly reported adverse reaction for LIDOCAINE HYDROCHLORIDE ANHYDROUS, manufactured by Spectra Medical Devices, LLC. There are 270 FDA adverse event reports linking LIDOCAINE HYDROCHLORIDE ANHYDROUS to INFUSION SITE SWELLING. This represents approximately 1.9% of all 13,967 adverse event reports for this drug.
Patients taking LIDOCAINE HYDROCHLORIDE ANHYDROUS who experience infusion site swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFUSION SITE SWELLING is a less commonly reported adverse event for LIDOCAINE HYDROCHLORIDE ANHYDROUS, but still significant enough to appear in the safety profile.
In addition to infusion site swelling, the following adverse reactions have been reported for LIDOCAINE HYDROCHLORIDE ANHYDROUS:
The following drugs have also been linked to infusion site swelling in FDA adverse event reports:
INFUSION SITE SWELLING has been reported as an adverse event in 270 FDA reports for LIDOCAINE HYDROCHLORIDE ANHYDROUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFUSION SITE SWELLING accounts for approximately 1.9% of all adverse event reports for LIDOCAINE HYDROCHLORIDE ANHYDROUS, making it a notable side effect.
If you experience infusion site swelling while taking LIDOCAINE HYDROCHLORIDE ANHYDROUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.